House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Hepatology

Cirrhosis in over 16s: assessment and management

NICE · 2023 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This NICE guideline (NG50) covers the assessment and management of cirrhosis in people over 16. The supplied text includes 2016 recommendations and 2023 updates. Topics are recognising risk, choosing diagnostic tests (mainly transient elastography), referral, and retesting. It also covers monitoring complication risk with MELD, hepatocellular carcinoma surveillance, and endoscopic detection and surveillance of oesophageal varices. Management topics are safe carvedilol and propranolol prescribing, primary prevention of decompensation, prevention of bleeding from medium or large varices, spontaneous bacterial peritonitis prophylaxis, antibiotics for upper GI bleeding, and TIPS for refractory ascites. Several beta-blocker uses were off-label in September 2023.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Recognising risk and diagnosing cirrhosis

  • Recognise the following groups as being at increased risk of cirrhosis: - people with hepatitis B infection - people with hepatitis C infection - people who misuse alcohol - people living with obesity (BMI 30 kg/m2 or higher) - people with type 2 diabetes [1]
  • Discuss with the person the accuracy, limitations and risks of the available diagnostic tests. Staff who perform or interpret non-invasive tests should be trained to do so. [1]
  • Offer transient elastography to diagnose cirrhosis in: - people with hepatitis C - men and people registered male at birth drinking over 50 units of alcohol a week for several months - women and people registered female at birth drinking over 35 units a week for several months - people diagnosed with alcohol-related liver disease [1]
  • In MASLD with advanced fibrosis (ELF score 10.51 or above), offer whichever is available of transient elastography or acoustic radiation force impulse imaging. [1]
  • Liver biopsy may be considered when transient elastography is unsuitable. [1]
  • Do not test for cirrhosis in people with obesity (BMI 30 kg/m2 or higher) or type 2 diabetes unless they have MASLD with advanced fibrosis (ELF score 10.51 or above). [1]
  • Routine laboratory liver blood tests should not be used to exclude cirrhosis. [1]
  • Offer retesting for cirrhosis every 2 years to: - people with alcohol-related liver disease - people with hepatitis C without a sustained virological response to antivirals - people with MASLD and advanced fibrosis [1]

Referral, monitoring complication risk and HCC surveillance

  • Refer anyone diagnosed with cirrhosis to a hepatology specialist. People who have, or are at high risk of, cirrhosis complications should be referred to a specialist hepatology centre. [1]
  • In compensated cirrhosis, calculate the MELD score every 6 months. A score of 12 or more may be considered to indicate high risk of complications. [1]
  • For people with cirrhosis without hepatitis B, offer HCC surveillance by ultrasound every 6 months, with or without serum alpha-fetoprotein. Do not offer surveillance to people receiving end of life care. [1]

Endoscopic detection of oesophageal varices

  • After diagnosis, offer upper GI endoscopy to detect varices. This does not apply to people planning to take carvedilol or propranolol to prevent decompensation. [1]
  • Offer surveillance endoscopy every 3 years to people whose previous endoscopy found no varices and who are not taking carvedilol or propranolol. [1]
  • If medium or large varices are found at endoscopy, consider band ligation during the same procedure. [1]

Carvedilol/propranolol and primary prevention of decompensation

  • Use carvedilol and propranolol cautiously in cirrhosis because they have greater heart rate and blood pressure effects. Avoid carvedilol in severe hepatic impairment, such as large-volume or refractory ascites. [1]
  • When starting carvedilol or propranolol in cirrhosis to prevent decompensation or bleeding from medium or large varices, use a low dosage, for example carvedilol 6.25 mg a day or propranolol 40 mg twice a day. Then titrate up or down according to heart and blood pressure monitoring. [1]
  • In confirmed or suspected clinically significant portal hypertension, consider beta-blockers to prevent decompensation. Examples are a hepatic venous pressure gradient over 10 mmHg or the presence of varices. Carvedilol is first choice; propranolol is second choice if carvedilol is contraindicated. This use was off-label in September 2023. [1]

Preventing bleeding from medium or large varices

  • For medium or large varices, discuss the benefits and harms of all options and explain what treatment involves. Ask about barriers to treatment, such as difficulty taking tablets regularly because of alcohol dependence or homelessness. [1]
  • Offer carvedilol or propranolol for medium or large varices. Offer band ligation instead if these drugs are not tolerated or contraindicated, or if the person cannot take tablets regularly. Carvedilol for this purpose was off-label in September 2023. [1]

SBP prophylaxis, GI bleeding and refractory ascites

  • Antibiotic prophylaxis against SBP is not routine in cirrhosis with ascites. [1]
  • Consider SBP prophylaxis only in two situations: - high risk from severe liver disease, for example ascitic protein of 15 g per litre or less, Child–Pugh score over 9, or MELD over 16 - infection could seriously affect care, such as waiting for a transplant or TIPS [1]
  • When SBP prophylaxis is given, follow local microbiological advice. Continue it until the ascites resolves. [1]
  • Offer prophylactic intravenous antibiotics to people with cirrhosis and upper GI bleeding. Review them in line with NICE antimicrobial stewardship guidance on prescribing intravenous antimicrobials. [1]
  • A TIPS procedure may be considered for refractory ascites in cirrhosis. [1]

Limitations and use

  • Applies to people over 16; younger people are not covered.
  • Diagnosis, reassessment and HCC surveillance in people with hepatitis B are deferred to NICE's chronic hepatitis B guideline and are not summarised here.
  • Assessment of advanced fibrosis in MASLD is deferred to NICE's MASLD guideline.
  • Research recommendations and later nonclinical rationale/update sections were not included in the supplied text.
  • Off-label status of carvedilol and propranolol uses is stated as of September 2023.
  • Tables and flowcharts in the original document were not interpreted.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Cirrhosis in over 16s: assessment and management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
6 July 2016
Publisher’s latest update
8 September 2023
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Recognising risk and diagnosing cirrhosis
  • Referral, monitoring complication risk and HCC surveillance
  • Endoscopic detection of oesophageal varices
  • Carvedilol/propranolol and primary prevention of decompensation
  • Preventing bleeding from medium or large varices
  • SBP prophylaxis, GI bleeding and refractory ascites
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House